Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a, Randomized, Double-Blind, Placebo-Controlled, Single Site, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of CSX-1004 Injection in Healthy Adults

Next Previous
Trial Profile

A Phase 1a, Randomized, Double-Blind, Placebo-Controlled, Single Site, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of CSX-1004 Injection in Healthy Adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CSX 1004 (Primary)
  • Indications Opioid-related disorders
  • Focus Adverse reactions; First in man
  • Sponsors Cessation Therapeutics

Most Recent Events

  • 21 Aug 2024 Status changed from recruiting to completed.
  • 19 Jun 2024 According to Cessation Therapeutics media release, the company announced the presentation of preliminary data from this trial as an oral presentation at the annual meeting of the College on Problems of Drug Dependence (CPDD) in Montreal on June 19 at 11:30 am ET.
  • 24 Aug 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top